ORCID Profile
0000-0002-7854-4302
Current Organisation
Eastern Health
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 25-08-2023
DOI: 10.1002/IJC.34245
Abstract: The pertuzumab study in the neoadjuvant setting for HER2+ nonmetastatic breast cancer in Australia (PeRSIA-ML39622) is an analysis of safety and effectiveness data from the pertuzumab patient registry. Although the prognosis of patients with early stage HER2+ breast cancer has been greatly improved by advances in chemotherapy approximately 25% to 30% of patients develop recurrent disease. Our study aimed to examine the effectiveness of neoadjuvant pertuzumab on surgical outcomes, describe the medium-term effectiveness outcomes of patients treated with pertuzumab, and describe the planned and actual anticancer treatment regimens that patients received. Deidentified data were collected from the patients' medical records and entered into REDCap, between March 2018 and July 2019 (n = 95). The adverse events (AEs) reported most frequently were diarrhea (20 21.1%), rash (4 4.2%), and LVSD (4 4.2% two patients during neoadjuvant treatment and two patients during adjuvant treatment). AEs, ≥Grade 3 were diarrhea (2 2.1%) and LVSD (1 1.1%). Following surgery, a breast pathological complete response (bpCR) was achieved in 65 patients (70.7% 95% CI: 60.2%-79.7%) and total pathological complete response (tpCR) in 59 patients (64.1% 95% CI: 53.4%-73.9%). All patients who did not achieve a tpCR obtained a partial response (33/92, 35.9%). Our study is the first to capture real-world data on the use of pertuzumab in the neoadjuvant setting in Australia. The effectiveness and safety data are consistent with those reported in clinical trials of pertuzumab in patients with HER2+ breast cancer, with no new safety concerns.
Publisher: Elsevier BV
Date: 08-2010
Publisher: Oxford University Press (OUP)
Date: 13-06-2015
DOI: 10.1111/BJD.13756
Abstract: The clinical behaviour and prognosis of primary melanomas harbouring BRAF mutations is not fully understood. To investigate the effect of mutation status on primary melanoma growth rate and melanoma-specific survival (MSS). A prospective cohort of 196 patients with stage I-III primary cutaneous melanoma were followed for a median of 92 months, pre-dating the institution of BRAF inhibitor therapy. Clinicopathological variables were correlated with mutation status and hazard ratios (HRs) estimated for MSS. Of 196 tumours, 77 (39.2%) were BRAF V600E, 10 (5.1%) BRAF V600K and 33 (16.8%) were NRAS mutant. BRAF V600E mutant melanomas were associated with favourable clinical characteristics and tended to be slower growing compared with BRAF V600K, NRAS mutant or BRAF/NRAS wild-type tumours (0.12 mm per month, 0.61 mm per month, 0.36 mm per month and 0.23 mm per month, respectively P = 0.05). There were 39 melanoma deaths, and BRAF mutant melanomas were associated with poorer MSS in stage I-III disease [HR 2.60, 95% confidence interval (CI) 1.20-5.63 P = 0.02] and stage I-II disease (HR 3.39, 95% CI 1.12-10.22 P = 0.03) after adjusting for other prognostic variables. Considered separately, BRAF V600E mutant melanomas were strongly associated with MSS independently of thickness and nodal status (HR 3.89, 95% CI 1.67-9.09 P < 0.01) but BRAF V600K mutant tumours were not (HR 1.19, 95% CI 0.36-3.92 P = 0.77). The presence of a BRAF mutation does not necessarily 'drive' more rapid tumour growth but is associated with poorer MSS in patients with early-stage disease.
Publisher: Wiley
Date: 22-06-2011
Publisher: Elsevier BV
Date: 04-2014
Publisher: Oxford University Press (OUP)
Date: 11-2013
DOI: 10.1093/JNCI/DJT311
Publisher: American Society of Clinical Oncology (ASCO)
Date: 11-2010
Abstract: As the complexity of cancer treatment increases so too has the need for coordination between health care professionals. Multidisciplinary meetings are a useful tool in treating patients with cancer and are shown to improve survival and adherence to evidence based-guidelines.
Publisher: Elsevier BV
Date: 05-2008
DOI: 10.1016/J.JHIN.2008.02.010
Abstract: We report the successful control of an outbreak of six cases of nosocomial invasive aspergillosis (IA) in our haematology unit coinciding with major hospital construction works. Infection control changes included unit relocation, impermeable barriers at construction site, face-masking and voriconazole prophylaxis of 18 further high-risk patients, none of which developed breakthrough IA. A multi-faceted pre-emptive approach involving clinicians, hospital management, engineering and building departments is essential in preventing nosocomial IA outbreaks.
No related grants have been discovered for Bianca Devitt.